Tonghua Dongbao Pharmaceuticals Co., Ltd (SHA: 600867) and Huisheng Biopharmaceutical Co., Ltd. announced a Commercialization Cooperation Agreement to jointly advance diabetes treatment in China. Under the agreement, Tonghua Dongbao secured exclusive commercialization rights in Mainland China for Huiyoujia (Insulin Degludec/Insulin Aspart) and Huiyouda (Insulin Degludec)—the first domestically produced biosimilars of these next‑generation basal insulins.
First domestically produced biosimilar of dual‑insulin preparation in China
Huiyouda
Insulin degludec (ultra‑long‑acting basal)
First domestic degludec biosimilar
Strategic Rationale
Resource Complementarity: Tonghua Dongbao brings established endocrinology commercial infrastructure (insulin glargine, recombinant human insulin market presence); Huisheng provides biosimilar R&D and manufacturing expertise.
First‑Mover Advantage: As the first domestic degludec biosimilars, Huiyoujia and Huiyouda can capture market share from Novo Nordisk’s originator products (Tresiba, Ryzodeg) before additional competitors enter.
Next‑Generation Insulin Access: Insulin degludec offers flat pharmacokinetic profiles and flexible dosing vs. older basal insulins; domestic production improves supply security and pricing competitiveness in China’s diabetes market.
Diabetes Market Growth: China has > 140 million diabetes patients; insulin degludec adoption is accelerating as physicians and patients seek reduced hypoglycemia risk and improved adherence.
Market Context
Factor
Impact
China Insulin Market
~ RMB 20 billion; dominated by Novo Nordisk, Eli Lilly, Sanofi; biosimilar entry accelerating
Degludec Differentiation
Ultra‑long duration (42+ hours); lower nocturnal hypoglycemia vs. glargine; growing preference in type 1 and type 2 diabetes
Tonghua Dongbao Position
Leading domestic insulin manufacturer; Huiyoujia/Huiyouda addition strengthens portfolio vs. Gan & Lee, Jiangsu Hengrui
National Reimbursement
Biosimilar pricing advantages support NRDL inclusion and volume expansion
Forward‑Looking Statements This brief contains forward‑looking statements regarding commercial launch timelines, market share capture, and manufacturing scale‑up. Actual results may differ due to risks including originator pricing responses, regulatory inspections, and competitive biosimilar launches.-Fineline Info & Tech
By Fineline Cube 